Rejubella 300mg PDO Filler
$92.00
Rejubella 300mg PDO Filler utilizes patented biodegradable poly-dioxanone microspheres (150mg) in CMC gel (150mg) for dual-action aesthetic correction. Its 10-60μm smooth particles provide immediate volume restoration while stimulating endogenous collagen production. Clinically validated by Osong Advanced Medical Innovation Foundation (Patent 10-2019-0124485), with complete 5-month biodegradation and natural long-term results.
| Mix-And-Match Quantity | Get More Discount | Final Price |
|---|---|---|
| 5-15 | 4% | $88.32 |
| 16-30 | 6% | $86.48 |
| 31-Unlimited | 8% | $84.64 |
Rejubella 300mg PDO Filler
Dual-Action Collagen Remodeling Dermal Filler
Advanced Collagen Remodeling Technology
Rejubella® is an FDA-equivalent Class III medical device utilizing biodegradable PDO microspheres (150mg) suspended in CMC gel (150mg) for volumetric restoration. Clinically proven to deliver immediate volume correction (1 week onset) while stimulating endogenous collagen synthesis (4 weeks). Its spherical particles (10-60μm) and 40-year safety profile ensure minimal inflammatory response, with complete biodegradation within 5 months, leaving exclusively autologous collagen for long-lasting results.
Clinical Superiority vs. Conventional Fillers
Enhanced Safety Profile
5-month full biodegradation versus PCL (1-4 years). Smooth spherical microspheres eliminate granuloma risks associated with PLLA crystalline structures.
Long-Term Efficacy
Natural collagen replacement maintains results beyond carrier degradation, avoiding repetitive supplementation needed with traditional fillers.
Multimodal Indications
Combines volumetric restoration with skin rejuvenation – effective for facial contours, static wrinkles, and skin texture optimization.
Precision Formulation
Biomaterial Engineering
- ▶ Microspheres: 150mg PDO (10-60μm)
- ▶ Carrier: 150mg CMC gel
- ▶ Particle structure: Spherical, smooth-surface
Packaging Configuration
- ▶ Unit capacity: 300mg/vial
- ▶ Formats: 1 vial/box & 5 vials/box
- ▶ Sterile medical device
Patented Innovation
Protected under Korean Patent No. 10-2019-0124485. Biodegradation timeline confirmed by Osong Advanced Medical Innovation Foundation.
Clinical Application Protocol
Reconstitution
Add 5ml sterile water + 1-2ml lidocaine via 18G needle
Suspension
Vigorous shaking until homogeneous mixture achieved
Aspiration
Transfer using 18G needle to syringe
Implantation
Deliver via 26G cannula to mid/deep dermis
Treatment Areas
▸ Facial volumization (temples/cheeks)
▸ Chin contour enhancement
▸ Static wrinkle correction
▸ Skin texture rejuvenation
Medical Usage Notice
Rejubella® is a Class III medical device for licensed practitioners only. Results vary based on individual tissue response and injection technique. All product specifications subject to Korean FDA regulations. Patent No. 10-2019-0124485 protected in South Korea.


Reviews
There are no reviews yet.